Top Markets
#1 Black Phoenix Black Phoenix +826.34%
#2 pipedog pipedog +28.14%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.27%
#4 SAFEcoin SAFEcoin +25.29%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +23.78%
#6 Bless Bless +22.81%
#7 PondCoin PondCoin +19.97%
#8 Beam Beam +19.73%
#9 Magma Finance Magma Finance +19.65%
#10 Asteroid Shiba Asteroid Shiba +17.65%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Rang in Aktien #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Aktienkurs
$32.88
Marktkapitalisierung
$2.08B
Veränderung (1 Tag)
-0.48%
Veränderung (1 Jahr)
96.77%
Land
US
Handel Zenas BioPharma, Inc. (ZBIO)

Kategorie

Healthcare
P/S-Verhältnis für Zenas BioPharma, Inc. (ZBIO)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Zenas BioPharma, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Zenas BioPharma, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH